drugset / Trial / NCT06095973

Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults

NCT06095973

Phase 1 Completed 40 enrolled G2GBio, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is to evaluate the safety and tolerability of single dose of GB-6002 (Ropivacaine) Local Infiltration in healthy male Adults. And, It is to compare pharmacokinetic characteristics of GB-6002 single dose injection with active comparator.

Timeline

Start
2023-10-24
Primary completion
2024-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropivacaine Other / unclassified Subcutaneous

Indications